Fridamycin A, a Microbial Natural Product, Stimulates Glucose Uptake without Inducing Adipogenesis
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea
Leibniz Institute for Natural Product Research and Infection Biology—Hans-Knöll-Institute, Beutenbergstraße 11a, 07745 Jena, Germany
Authors to whom correspondence should be addressed.
These authors contributed equality to this work.
Nutrients 2019, 11(4), 765; https://doi.org/10.3390/nu11040765
Received: 6 March 2019 / Revised: 27 March 2019 / Accepted: 27 March 2019 / Published: 1 April 2019
Type 2 diabetes is a complex, heterogeneous, and polygenic disease. Currently, available drugs for treating type 2 diabetes predominantly include sulfonylureas, α-glucosidase inhibitors, and biguanides. However, long-term treatment with these therapeutic drugs is often accompanied by undesirable side effects, which have driven interest in the development of more effective and safer antidiabetic agents. To address the urgent need for new chemical solutions, we focused on the analysis of structurally novel and/or biologically new metabolites produced by insect-associated microbes as they have recently been recognized as a rich source of natural products. Comparative LC/MS-based analysis of Actinomadura sp. RB99, isolated from a fungus-growing termite, led to the identification of the type II polyketide synthase-derived fridamycin A. The structure of fridamycin A was confirmed by 1H NMR data and LC/MS analysis. The natural microbial product, fridamycin A, was examined for its antidiabetic properties in 3T3-L1 adipocytes, which demonstrated that fridamycin A induced glucose uptake in 3T3-L1 cells by activating the AMP-activated protein kinase (AMPK) signaling pathway but did not affect adipocyte differentiation, suggesting that the glucose uptake took place through activation of the AMPK signaling pathway without inducing adipogenesis. Our results suggest that fridamycin A has potential to induce fewer side effects such as weight gain compared to rosiglitazone, a commonly used antidiabetic drug, and that fridamycin A could be a novel potential therapeutic candidate for the management of type 2 diabetes.